Literature DB >> 3154919

Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.

L H Opie1.   

Abstract

Beta-adrenergic blockade is established therapy in the management of both hypertension and angina pectoris. This review evaluates the use of combined alpha-adrenergic and beta-adrenergic blockade for these conditions, with reference to labetalol. There are three major differences between labetalol and propranolol or similar conventional beta-blockers. First, in the mechanism of the antihypertensive effect, peripheral vasodilation plays a prominent role during the use of labetalol. In particular, acute therapy with labetalol rapidly reduces the blood pressure because of this reduction in the systemic vascular resistance. During prolonged therapy with labetalol over many years, blood pressure remains reduced with a sustained fall in the systemic vascular resistance. Second, in patients with combined hypertension and angina pectoris, fixed doses of labetalol (200 mg twice daily) gave the same blood pressure values, effort tolerance, and nitrate usage as did atenolol 100 mg once daily in a double-blind, double-dummy, crossover study. Labetalol gave higher heart rates at rest and during exercise (both p less than 0.01). The higher heart rate with labetalol could be an advantage in some patients with effort angina and a disadvantage in others. Third, in hypertensive asthmatics, labetalol appears to have a relative bronchosparing effect, when compared with propranolol. The possession by labetalol of beta2-stimulating qualities (intrinsic sympathomimetic activity) may explain part of the dilating effect and the bronchosparing quality. Thus labetalol 1) lowers blood pressure by a mechanism involving vasodilation, 2) has an equiantianginal effect to atenolol yet a higher heart rate, and 3) may be bronchosparing. Differences among various beta-blockers may be important in matching the properties of the beta-blocker chosen to the requirements of the individual patient.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3154919     DOI: 10.1007/bf00054645

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  56 in total

1.  Comparison of metabolic and vasoconstrictor stimuli on coronary vascular resistance in man.

Authors:  G H Mudge; S Goldberg; S Gunther; T Mann; W Grossman
Journal:  Circulation       Date:  1979-03       Impact factor: 29.690

2.  Labetalol compared with propranolol in the treatment of black hypertensive patients.

Authors:  E Saunders; C Curry; J Hinds; B W Kong; M Medakovic; M Poland; K Roper
Journal:  J Clin Hypertens       Date:  1987-09       Impact factor: 3.738

Review 3.  A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.

Authors:  R T Brittain; G P Levy
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

4.  Altered adrenergic activity in coronary arterial spasm: insight into mechanism based on study of coronary hemodynamics and the electrocardiogram.

Authors:  D R Ricci; A E Orlick; P R Cipriano; D F Guthaner; D C Harrison
Journal:  Am J Cardiol       Date:  1979-06       Impact factor: 2.778

5.  Role of alpha-adrenergic coronary tone in exercise-induced angina pectoris.

Authors:  G M Berkenboom; M Abramowicz; P Vandermoten; S G Degre
Journal:  Am J Cardiol       Date:  1986-02-01       Impact factor: 2.778

6.  Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity.

Authors:  R B George; R W Light; L D Hudson; S A Conrad; K Chetty; K Manocha; J G Burford
Journal:  Chest       Date:  1985-12       Impact factor: 9.410

7.  Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Am J Med       Date:  1983-10-17       Impact factor: 4.965

8.  Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries.

Authors:  D Opherk; G Mall; H Zebe; F Schwarz; E Weihe; J Manthey; W Kübler
Journal:  Circulation       Date:  1984-01       Impact factor: 29.690

9.  Alpha-adrenergic blockade for variant angina: a long-term, double-blind, randomized trial.

Authors:  M D Winniford; N Filipchuk; L D Hillis
Journal:  Circulation       Date:  1983-06       Impact factor: 29.690

Review 10.  Labetalol. Current research and therapeutic status.

Authors:  J D Wallin; W M O'Neill
Journal:  Arch Intern Med       Date:  1983-03
View more
  3 in total

Review 1.  The vasodilatory beta-blockers.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

Review 2.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

3.  Maternal ethnicity and its impact on the haemodynamic and blood pressure response to labetalol for the treatment of antenatal hypertension.

Authors:  D Stott; M Bolten; D Paraschiv; I Papastefanou; J B Chambers; N A Kametas
Journal:  Open Heart       Date:  2016-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.